[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"intravascular-thrombosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:intravascular-thrombosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,59],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":39,"overallStatus":46,"whyStopped":4,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":58},"100652013","angiovac-aspiration-therapy-registry-100652013",false,"NCT07769320","AngioVac Aspiration Therapy Registry","A Multicenter, International, Retrospective Observational Study Evaluating the Safety and Effectiveness of the AngioVac System Across Clinical Indications","AVATaR","Inclusion Criteria:\n\n1. Age ≥18 years at time of AngioVac procedure\n2. Patient underwent percutaneous AngioVac aspiration (any AngioVac model or version used clinically during study period)\n3. Procedure performed within study period (January 2018 (or site's institutional start date) - June 2026)\n4. Written informed consent OR documented waiver\u002Fexemption from ethics authority (per local regulations per GDPR)\n\nExclusion Criteria:\n\n1. Insufficient documentation to assess primary safety or effectiveness endpoints (e.g. defined as \\>20% missing data in core endpoint variables)\n2. Patient objection to retrospective data use (where required by local law; GDPR Article 21 opt-out; honored without study impact)\n3. Non-AngioVac procedures: Patients undergoing thrombus\u002Fvegetation removal by surgery or other percutaneous devices only (not AngioVac)","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","As a structured, multinational retrospective registry the AVATAR Registry addresses the following scientific aspects through systematic data collection, centralized quality control, and robust statistical analysis in patients that were treated with the AngioVac Aspiration System:\n\n1. Quantify Real-World Safety: Composite adverse event rates across diverse populations and indications\n2. Assess Effectiveness: Technical and clinical success rates stratified by indication\n3. Identify Predictors: Clinical, procedural, and anatomical factors predicting success versus complications\n4. Generate Publishable Cohorts: Sufficient statistical power (approx. 1000 patients across 8 indication cohorts) for:\n\n   * Indication-specific outcomes\n   * Multivariable prediction models\n   * Time-to-event analyses (30-day and 12-month mortality)\n5. Establish Best Practices: Evidence-based recommendations for patient selection, procedural technique, and follow-up",[25,26,27,28,29,30,31,32,33,34,35,36,37,38],"Intracardiac Thrombus","Intracardiac Mass","Intravascular Thrombosis","Vegetation; Heart","Vegetation; Endocarditis","Vegetation on Catheter","Thrombus of Right Atrium","Thrombus of Right Ventricle","Thrombus Inferior Vena Cava","Thrombus of Pacemaker Electrode","Endocarditis Infective","Endocarditis, Bacterial","Thrombus of Pulmonary Artery","Thrombus on Catheter",[40,41,42,43,44,45],"Percutaneous aspiration","Intracardiac thrombus","Intravascular thrombus","Vegetation","Endocarditis","CIED lead associated vegetation","NOT_YET_RECRUITING","2026-08-12",{"date":49,"type":50},"2026-08-17","ACTUAL",{"date":52,"type":21},"2026-10-01",{"date":54,"type":21},"2027-12-31",{"name":56,"class":57},"Charite University, Berlin, Germany","OTHER",1,{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":66,"targetDuration":4,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":58},"100413541","intra-arterial-neuroprotective-strategy-for-ischemic-stroke-patients-with-endovascular-therapy-insist-et-100413541","NCT04664933","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET)","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With Endovascular Therapy (INSIST-ET): One Single Center, Safety and Feasibility Study","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Acute ischemic stroke patients who is eligible for endovascular treatment;\n3. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia (\\\u003C80000\u002Fmm3);\n3. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n4. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n5. Unsuitable for this clinical studies assessed by researcher.",{"count":67,"type":21},30,"INTERVENTIONAL",[70],"NA","To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who received recanalization operation.",[73,27,74],"Stroke, Ischemic","Mechanical Thrombectomy","RECRUITING","2025-08-20",{"date":78,"type":50},"2025-08-21",{"date":80,"type":50},"2020-12-01",{"date":82,"type":21},"2026-05-31",{"name":84,"class":57},"Hui-Sheng Chen"]